抗体药物偶联物靶点在卵巢癌主要组织学类型中呈现高度差异表达
该研究采用组织芯片免疫组化评估高级别浆液性(HGSOC,n=331)、子宫内膜样(EnOC,n=101)和透明细胞卵巢癌(CCOC,n=60)中FOLRα、TROP2和B7-H4的表达。FOLRα在HGSOC中表达最高,EnOC和CCOC多为阴性;B7-H4在三型中均常见表达;TROP2阳性主要见于HGSOC和EnOC。作者认为设计和分析ADC临床研究时应充分考虑组织学类型和靶点表达水平。
要点
- FOLRα在HGSOC中表达最高,EnOC和CCOC通常为FOLRα阴性。
- B7-H4在HGSOC、EnOC和CCOC中均频繁表达。
- TROP2阳性主要限于HGSOC和EnOC,CCOC大多为TROP2阴性。
核心结论
- EnOC和CCOC通常为FOLRα阴性,而HGSOC、EnOC和CCOC频繁表达B7-H4;TROP2阳性限于HGSOC和EnOC。
- 作者认为设计和分析ADC临床研究时应仔细考虑组织学类型和ADC靶点表达水平。
研究设计与样本
- 采用组织芯片免疫组化评估卵巢癌主要组织学类型中ADC靶点FOLRα、TROP2和B7-H4的表达水平。
- 纳入高级别浆液性卵巢癌(HGSOC,n=331)、子宫内膜样卵巢癌(EnOC,n=101)和透明细胞卵巢癌(CCOC,n=60)患者队列。
- 表达程度通过膜组织学评分(histoscore)量化。
主要发现
- FOLRα组织学评分≥50者在HGSOC为70.9%,在EnOC为21.1%,在CCOC为29.3%。
- B7-H4组织学评分≥50者在HGSOC为99.7%,在EnOC为89.8%,在CCOC为80.7%。
- TROP2组织学评分≥50者在HGSOC为54.8%,在EnOC为57.7%;CCOC中89.3%组织学评分<50。
- ADC靶点表达与HGSOC分子亚型(BRCA1/2突变、CCNE1获得、其他)或EnOC分子亚型(TP53突变、CTNNB1突变、POLE突变、MMR缺陷、无特定分子谱)无显著关联。
- 在CCOC中,ARID1A/B突变与较低的B7-H4表达相关(P-adj=0.024)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antibody-drug conjugates (ADCs) are emerging anti-cancer agents. The folate receptor alpha (FOLRα)-directed ADC mirvetuximab soravtansine recently demonstrated clinical activity in platinum-resistant ovarian cancer, with other ADCs currently in development. The relative expression of FOLRα and other ADC targets is largely unknown across ovarian cancer histotypes. METHODS: Expression levels of the ADC targets FOLRα, TROP2 and B7-H4 were assessed by immunohistochemistry in patient cohorts using tumour tissue microarrays of the major ovarian cancer histotypes: high grade serous (HGSOC, n = 331); endometrioid (EnOC, n = 101) and clear cell ovarian carcinoma (CCOC, n = 60). Degree of expression was quantified by membrane histoscore. RESULTS: We observed differences in ADC target expression patterns across ovarian cancer histotypes. FOLRα expression was highest in HGSOC, with few EnOC or CCOC demonstrating positivity (HGSOC: 70.9 % FOLRα histoscore ≥50 vs 21.1 % and 29.3 % in EnOC and CCOC). B7-H4 was expressed in HGSOC, EnOC and CCOC (99.7 %, 89.8 % and 80.7 % with histoscore ≥50). CCOC were mostly TROP2 negative (89.3 % with histoscore <50); a subset of HGSOC and EnOC expressed TROP2 (54.8 % and 57.7 % with histoscore ≥50, respectively). There was no significant association between ADC target expression and molecular subtypes of HGSOC (BRCA1/2-mutant, CCNE1-gained, other) or EnOC (TP53-mutant, CTNNB1-mutant, POLE-mutant, MMR deficient, no specific molecular profile). In CCOC, ARID1A/B mutation was associated with lower B7-H4 expression (P-adj=0.024). CONCLUSION: EnOC and CCOC are usually FOLRα negative, while HGSOC, EnOC and CCOC frequently express B7-H4. TROP2 positivity is limited to HGSOC and EnOC. Careful consideration of histotype and ADC target expression levels is warranted when designing and analysing clinical studies of ADCs.
引用
- Porter JM, Jin C, Churchman M, et al. Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer. Eur J Cancer. 2025. PMID: 40446758. doi:10.1016/j.ejca.2025.115522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。